The increasing focus of big pharma companies on specific therapeutic categories can leave promising candidates in out-of-favour conditions out in the cold, but Merck KGaA has tackled the issue head on by licensing a potentially disease-modifying osteoarthritis program to Novartis AG, in a deal valued at €450m ($527m).
Merck KGaA has out-licensed M6495, a Phase II-ready anti-ADAMTS5 Nanobody, to Novartis for an upfront payment of €50m. The Darmstadt,...








